Adenovirus Production via High-Density Perfusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for adenovirus production, particularly for serotype 35, face challenges in achieving high yields and maintaining productivity at high cell densities, leading to inefficiencies and high capital investment requirements for large-scale bioreactor facilities, and existing processes struggle to support global demand for adenovirus-based vaccines.
Innovation Solution
A method involving culturing producer cells in suspension with an alternating tangential flow perfusion system, infecting at cell densities between 10×10^6 and 16×10^6 viable cells/mL, and further culturing to propagate recombinant adenovirus serotype 35, allowing for high-yield production and optimized downstream processing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If scaling up to 10,000 L bioreactor is implemented, then production capacity increases to meet global demand, but capital investment becomes prohibitively high
Solution Approach 1:
The patent changes the critical parameter of cell density at infection from conventional 0.5-1×10^6 cells/mL to greater than 1×10^6 cells/mL. This parameter change enables higher virus yields per cell, allowing production of 1.5×10^19 VP/year in 1000 L or smaller bioreactors rather than requiring 10,000 L facilities, thus reducing CAPEX while maintaining productivity
Solution Approach 2:
The patent performs preliminary optimization of cell density parameters before scale-up. By establishing the optimal cell density range (>1×10^6 cells/mL) through prior experimentation, the patent enables direct scaling to production without requiring excessive bioreactor volume, thereby avoiding prohibitive capital investment
2Productivity
If adhering to conventional cell density at infection (0.5-1×10^6 cells/mL), then specific virus productivity per cell is maintained, but total virus yield is insufficient to meet global demand
Solution Approach 1:
The patent fundamentally changes the cell density parameter from 0.5-1×10^6 cells/mL to >1×10^6 cells/mL. This parameter change results in higher specific productivity per cell and dramatically increases total virus yield, enabling meeting of global vaccine demand without requiring proportional increases in bioreactor capacity
3Quantity of substance
If increasing cell density beyond 1×10^6 cells/mL, then total virus yield increases, but specific productivity per cell drops abruptly
Solution Approach 1:
The patent identifies and implements a new optimal parameter range for cell density at infection (>1×10^6 cells/mL) that overturns the conventional wisdom of the breakpoint at 1×10^6 cells/mL. Within this new parameter range, both specific productivity per cell and total virus yield increase simultaneously, resolving the contradiction between the two productivity metrics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases adenovirus serotype 35 yields, achieving concentrations of at least 1×10^12 virus particles/mL, reducing the need for large bioreactor facilities and lowering production costs, while maintaining high virus quality and productivity.
Implementation Method 1
culturing producer cells in suspension with an alternating tangential flow perfusion system
Data Source
AI summary
The invention provides methods for large-scale production of recombinant adenovirus 35, using perfusion systems and infection at very high-cell densities.